The bipartisan legislation would prohibit federal contracts, loans or grants to any Chinese “biotechnology company of concern.” That would apply to companies with research agreements with the National Institutes of Health or sales to the Department of Veterans Affairs or the Department of Defense, including TRICARE.
Because reimbursements are not considered a federal contract, the updated legislation would not affect Medicare and Medicaid payments, according to staff on the 网页链接{House Oversight and Accountability Committee}, which will be voting on the bill.